Gilead Says Remdesivir Will Change Congress’ Attitude On Drug Prices

By Ariel Cohen / May 7, 2020 at 11:39 AM
Gilead executives said they are already seeing lawmakers change their attitudes toward drug price controls as drug makers develop desperately needed drugs and vaccines against COVID-19. “The tone is different in Washington,” Gilead CEO Daniel O’Day said Thursday (April 30) during a first quarter earnings call. The call came a day after the company announced promising initial results from clinical trials of its antiviral remdesivir in treating COVID-19. Company executives hope to make enough of the drug to treat 1...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.